Publications by authors named "Harold Koendgen"

Claim this Profile
C
Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.
Ralph Hb Benedict, Ludwig Kappos, Aaron Miller, Hans-Peter Hartung, James Overell, Harold Koendgen

Mult Scler Relat Disord· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Ludwig Kappos, Anthony Traboulsee, David K B Li, Amit Bar-Or, Frederik Barkhof, Harold Koendgen

J Neurol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
Ahmed Abdelhak, Kai Antweiler, Markus C Kowarik, Makbule Senel, Joachim Havla, Harold Koendgen

Mult Scler Relat Disord· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Estimating drug concentration-response relationships by applying causal inference methods for continuous point exposures and time-to-event outcomes.
Sean Yiu, Qing Wang, Francois Mercier, Marianna Manfrini, Harold Koendgen

Stat Methods Med Res· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Amit Bar-Or, Gian-Andrea Thanei, Christopher Harp, Corrado Bernasconi, Ulrike Bonati, Harold Koendgen

EBioMedicine· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Stephen L Hauser, Amit Bar-Or, Martin S Weber, Heidemarie Kletzl, Andreas Günther, Harold Koendgen

Neurol Neuroimmunol Neuroinflamm· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial.
Andrew L Mammen, Anthony A Amato, Mazen M Dimachkie, Hector Chinoy, Yessar Hussain, Harold Koendgen

Lancet Rheumatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.
Douglas L Arnold, Till Sprenger, Amit Bar-Or, Jerry S Wolinsky, Ludwig Kappos, Harold Koendgen

Mult Scler· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Gavin Giovannoni, Ludwig Kappos, Jerome de Seze, Stephen L Hauser, James Overell, Harold Koendgen

Eur J Neurol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis.
Stephen L Hauser, Ludwig Kappos, Xavier Montalban, Licinio Craveiro, Cathy Chognot, Harold Koendgen

Neurology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in ocrelizumab-treated people with multiple sclerosis.
Richard Hughes, Louise Whitley, Kocho Fitovski, Hans-Martin Schneble, Erwan Muros, Harold Koendgen

Mult Scler Relat Disord· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Jerry S Wolinsky, Douglas L Arnold, Bruno Brochet, Hans-Peter Hartung, Xavier Montalban, Harold Koendgen

Lancet Neurol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of natalizumab on MRI outcomes and no evidence of disease activity in relapsing-remitting multiple sclerosis patients treated in a Czech Republic real-world setting: A longitudinal, retrospective study.
Dana Horakova, Tomas Uher, Jan Krasensky, Zdeněk Seidl, Annemie Ribbens, Harold Koendgen

Mult Scler Relat Disord· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Ludwig Kappos, Jerry S Wolinsky, Gavin Giovannoni, Douglas L Arnold, Qing Wang, Harold Koendgen

JAMA Neurol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Bruno Brochet, Harold Koendgen

Neurology· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series.
Richard Hughes, Rosetta Pedotti, Harold Koendgen

Mult Scler Relat Disord· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Frederik Barkhof, Ludwig Kappos, Jerry S Wolinsky, David K B Li, Amit Bar-Or, Harold Koendgen

Neurology· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Maria Trojano, Helmut Butzkueven, Ludwig Kappos, Heinz Wiendl, Tim Spelman, Harold Koendgen

Mult Scler Relat Disord· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Ludwig Kappos, Helmut Butzkueven, Heinz Wiendl, Timothy Spelman, Fabio Pellegrini, Harold Koendgen

Mult Scler· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Pei-Ran Ho, Harold Koendgen, Nolan Campbell, Bill Haddock, Sandra Richman

Lancet Neurol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.
Gavin Giovannoni, Gary Cutter, Maria Pia Sormani, Shibeshih Belachew, Robert Hyde, Harold Koendgen

Mult Scler Relat Disord· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCV® DxSelect™ antibody assay.
Denise Campagnolo, Qunming Dong, Lily Lee, Pei-Ran Ho, Diogo Amarante, Harold Koendgen

J Neurovirol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for characterizing the risk of PML in natalizumab-treated patients.
Harold Koendgen, Pei-Ran Ho, Ih Chang

Mult Scler Relat Disord· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis